These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7841703)

  • 1. Final height in girls with central precocious puberty: comparison of two different luteinizing hormone-releasing hormone agonist treatments.
    Antoniazzi F; Cisternino M; Nizzoli G; Bozzola M; Corrias A; De Luca F; De Sanctis C; Rigon F; Zamboni G; Bernasconi S
    Acta Paediatr; 1994 Oct; 83(10):1052-6. PubMed ID: 7841703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group.
    Partsch CJ; Hümmelink R; Peter M; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Horm Res; 1993; 39(3-4):111-7. PubMed ID: 8262471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison between complete and incomplete suppression of the hypophyseal-gonadal axis in girls with central precocious puberty: effect on growth and prospective final height].
    Partsch CJ; Hümmelink R; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Monatsschr Kinderheilkd; 1993 Dec; 141(12):935-9. PubMed ID: 8114776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variations in pituitary-gonadal suppression during intranasal buserelin and intramuscular depot-triptorelin therapy for central precocious puberty. Belgian Study Group for Pediatric Endocrinology.
    Heinrichs C; Craen M; Vanderschueren-Lodeweyckx M; Malvaux P; Fawe L; Bourguignon JP
    Acta Paediatr; 1994 Jun; 83(6):627-33. PubMed ID: 7919761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of luteinizing hormone-releasing hormone agonists on final height in luteinizing hormone-releasing hormone-dependent precocious puberty.
    Oerter KE; Manasco PK; Barnes KM; Jones J; Hill S; Cutler GB
    Acta Paediatr Suppl; 1993 Mar; 388():62-8; discussion 69. PubMed ID: 8329833
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution.
    Pucarelli I; Segni M; Ortore M; Arcadi E; Pasquino AM
    J Pediatr Endocrinol Metab; 2003 Sep; 16(7):1005-10. PubMed ID: 14513877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up and final height in girls with central precocious puberty treated with luteinizing hormone-releasing hormone analogue nasal spray.
    Cacciari E; Cassio A; Balsamo A; Colli C; Cicognani A; Pirazzoli P; Tani G; Brondelli L; Mandini M; Bovicelli L
    Arch Pediatr Adolesc Med; 1994 Nov; 148(11):1194-9. PubMed ID: 7921123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
    Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F
    J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females.
    Bertelloni S; Baroncelli GI; Sorrentino MC; Perri G; Saggese G
    Eur J Pediatr; 1998 May; 157(5):363-7. PubMed ID: 9625331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
    Lanes R; Soros A; Jakubowicz S
    J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center.
    Chung LY; Kang E; Nam HK; Rhie YJ; Lee KH
    J Korean Med Sci; 2021 Aug; 36(34):e219. PubMed ID: 34463062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Improvement of expected and final height in girls with central precocious puberty treated with gonadotropin releasing hormone analogues].
    Gómez F; Picó AM; Vargas F; Mauri M
    Med Clin (Barc); 1996 Nov; 107(18):681-4. PubMed ID: 9082075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. End results in central precocious puberty with GnRH analog treatment: the data of the Italian Study Group for Physiopathology of Puberty.
    Antoniazzi F; Arrigo T; Cisternino M; Galluzzi F; Bertelloni S; Pasquino AM; Borrelli P; Osio D; Mengarda F; De Luca F; Tatò L
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():773-80. PubMed ID: 10969920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to menarche and final height after histrelin implant treatment for central precocious puberty.
    Gillis D; Karavani G; Hirsch HJ; Strich D
    J Pediatr; 2013 Aug; 163(2):532-6. PubMed ID: 23485026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined therapy with GnRH analog plus growth hormone in central precocious puberty.
    Pucarelli I; Segni M; Ortore M; Moretti A; Iannaccone R; Pasquino AM
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():811-20. PubMed ID: 10969926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Short-term comparison of the treatment of precocious puberty with 2 different LHRH antagonists (buserelin and long-acting triptorelin). An endocrinologic and echographic study].
    Cicognani A; Cacciari E; Balsamo A; Cassio A; Papasodero A; Bellizzi M; Guacci P; Zappulla F
    Pediatr Med Chir; 1994; 16(1):43-8. PubMed ID: 8029088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty].
    Liang Y; Wei H; Zhang JL; Hou L; Luo XP
    Zhonghua Er Ke Za Zhi; 2004 Nov; 42(11):845-9. PubMed ID: 15631714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of long-acting luteinizing-hormone-releasing hormone agonist in central precocious puberty.
    Swaenepoel C; Chaussain JL; Roger M
    Horm Res; 1991; 36(3-4):126-30. PubMed ID: 1840142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of combined Gn-RH agonist and hGH therapy for better attining the goals in precocious puberty treatment.
    Tatò L; Saggese G; Cavallo L; Antoniazzi F; Corrias A; Pasquino AM; Cisternino M
    Horm Res; 1995; 44 Suppl 3():49-54. PubMed ID: 8719441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.